Clinical trials: Empagliflozin
Type2 Diabetes
The Efficacy of Sodium-glucose Co-transporter 2 Inhibitor or Dipeptidyl Peptidase-4 Inhibitor in Type 2 Diabetes Patients With Premix Insulin
The population of type 2 diabetes increased enormously worldwide. As disease progression, uncontrolled type 2 diabetes patients need multiple daily insulin injections, but the risk of body weight gain and hypoglycemia will…
- Trial name
- NCT03458715
- Testing
- SGLT2 inhibitor (Empagliflozin 25 MG), DPP4 inhibitor (Linagliptin 5 MG)
- Where
- Taiwan
- Volunteers
- 120 people
- Sponsor
- Mackay Memorial Hospital
Healthy
Empa/Lina FDC Food Effect Study (Japan)
The trial will be performed as an open-label, randomised, single-dose, two-sequence crossover design for the assessment of effect of food on bioavailability of empagliflozin / linagliptin fixed dose combination (FDC) tablet.
- Trial name
- NCT02815644
- Testing
- empagliflozin/linagliptin FDC
- Where
- Japan
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Heart Failure With Preserved Ejection Fraction, Chronic Heart Failure
Emulation of the EMPEROR-Preserved Trial Using Healthcare Claims Data
Investigators are building an empirical evidence base for real world data through large-scale emulation of randomized controlled trials.
- Conditions
- Heart Failure With Preserved Ejection Fraction, Chronic Heart Failure, Type 2 Diabetes Mellitus
- Trial name
- NCT07599293
- Testing
- Empagliflozin, Sitagliptin
- Where
- United States
- Volunteers
- 39,614 people
- Sponsor
- Brigham and Women's Hospital
Heart Failure of Reduced Ejection Fraction (HFrEF)
Real-world Comparative Effectiveness and Safety of Jardiance in Chinese Patients With Heart Failure of Reduced Ejection Fraction
This study is to provide the effectiveness and safety evidence in patients with heart failure of reduced ejection fraction (HFrEF) initiating Jardiance in real clinical practice in a larger Chinese population.
- Trial name
- NCT07044700
- Testing
- Jardiance, non-SGLT2 inhibitors
- Where
- China
- Volunteers
- 5,000 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus Type 2
Effect of Empagliflozin on Macrovascular and Microvascular Circulation and on Endothelium Function
Empagliflozin may lead to improved vascular and endothelial function in the macro- (pulse wave reflection) and microcirculation (retinal circulation) and improve cardiovascular risk factors, imparticular by effectively…
- Trial name
- NCT02471963
- Testing
- Empagliflozin
- Where
- Germany
- Volunteers
- 74 people
- Sponsor
- University of Erlangen-Nürnberg Medical School
Diabetes Mellitus, Type 2, Hypertension
24 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus and Hypertension
This trial is designed to investigate the efficacy and safety of empagliflozin compared with placebo in hypertensive black/African Americans with type 2 Diabetes Mellitus.
- Trial name
- NCT02182830
- Testing
- Empagliflozin low dose, Empagliflozin high dose
- Where
- 92 sites in United States
- Volunteers
- 166 people
- Sponsor
- Boehringer Ingelheim
Pharmacokinetic Parameters
Pharmacokinetics and Bioequivalence of Two Empagliflozin, With Evaluation in Healthy Jordanian Subjects Under Fasting and Fed Conditions
Background: The current study is a randomized, open-label, two-period, two-sequence, two-way crossover pharmacokinetic study in healthy Jordanian subjects to evaluate the pharmacokinetics and bioequivalence profile of two…
- Trial name
- NCT05229796
- Testing
- Empagliflozin 10 mg Tab
- Where
- Jordan
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Mutah University
Kidney Disease, Chronic
Post Marketing Surveillance of JARDIANCE in Chronic Kidney Disease
Study objective is to investigate the safety and effectiveness of long-term daily use of JARDIANCE® Tablets in patients with chronic kidney disease under real-world use.
- Trial name
- NCT06527846
- Testing
- JARDIANCE®
- Where
- Japan
- Volunteers
- 1,024 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes
SGLT2 Inhibition: Uric Acid Excretion Study
The current study investigates the effects of SGLT2 inhibitor empagliflozin on uric acid excretion.
- Trial name
- UREX (NCT05210517)
- Testing
- Empagliflozin 25 MG, Benzbromaron, Empagliflozin 25 MG + benzbromarone 100 mg
- Where
- Netherlands
- Volunteers
- 10 people
- Sponsor
- Amsterdam UMC, location VUmc
Coronary Artery Disease, Atherosclerosis
Aggressive Risk-Prevention Therapies for Coronary Atherosclerotic Plaque (ART-CAP)
The purpose of this study is to evaluate the role of coronary CT angiogram (CCTA) as a superior guide for the assessment of coronary artery plaque and guiding treatment decisions.
- Conditions
- Coronary Artery Disease, Atherosclerosis, Heart Attack
- Trial name
- ARTCAP (NCT06280976)
- Testing
- Statin, Aspirin tablet, Nexlizet
- Where
- United States
- Sponsor
- University of Louisville
Diabetes Mellitus, Type 1
Safety and Efficacy of Empagliflozin (BI 10773) in Type 1 Diabetes Mellitus Patients With or Without Renal Hyperfiltration
This open-label study aims to evaluate the impact of BI 10773 treatment on glomerular filtration rate under controlled conditions of euglycaemia and hyperglycaemia in subjects with type 1 diabetes mellitus with or without renal…
- Trial name
- NCT01392560
- Testing
- BI 10773
- Where
- Canada
- Volunteers
- 52 people
- Sponsor
- Boehringer Ingelheim
Cirrhotic Cardiomyopathy, Empagliflozin
DICE Study- Diastolic Improvement With Carvedilol & Empagliflozin in Patients With Cirrhosis
1. This proposed double-blind placebo controlled randomized controlled trial incorporates recent advances in management of heart failure and portal hypertension using the SGLT-2 inhibitor i.e. EMPAGLIFLOZIN.
- Conditions
- Cirrhotic Cardiomyopathy, Empagliflozin, Cardiometabolic Risk Factors, Cirrhosis
- Trial name
- DICE (NCT07322237)
- Testing
- Empagliflozin + Carvedilol, Carvedilol
- Where
- India
- Volunteers
- 400 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Diabetes Mellitus, Type 2
Esgliteo Post Marketing Surveillance (PMS) in Korean Patients With Type 2 Diabetes Mellitus
The objectives of this study are to monitor the safety and effectiveness of Esgliteo in Korean patients with type 2 diabetes mellitus in a routine clinical practice setting.
- Trial name
- NCT05130463
- Testing
- Empagliflozin/Linagliptin
- Where
- 30 sites in South Korea
- Volunteers
- 1,053 people
- Sponsor
- Boehringer Ingelheim
Diabete Mellitus, Heart Failure
Effect of Empagliflozin 10 vs 25 mg on LV Remodeling in Diabetic Patients With Anterior STEMI With Reduced LVEF
This study is investigating how the medication Empagliflozin affects the heart's structure and function in patients with heart disease.
- Conditions
- Diabete Mellitus, Heart Failure, Remodeling, Left Ventricle
- Trial name
- EMPA-DMMI (NCT07169981)
- Testing
- Empagliflozin 10 MG [Jardiance], empagliflozin (Jardiance) 25 mg
- Where
- Egypt
- Volunteers
- 200 people
- Sponsor
- Ain Shams University
Diabetes Mellitus, Type 2
Meta-analysis in Post-marketing Surveillances for SGLT2 Inhibitors in Patients With Type 2 Diabetes Mellitus
The purpose of this study is to integrate the post-marketing surveillances data (Specified use-results surveys on long-term treatment) of the 6 SGLT2 inhibitors approved or applied in Japan and to evaluate the safety and efficacy…
- Trial name
- NCT02284269
- Testing
- SGLT2 Inhibitors
- Volunteers
- 18,000 people
- Sponsor
- Pharmaceuticals and Medical Devices Agency, Japan
Inappropriate ADH Syndrome
Effects of Empagliflozin an SGLT2-Inhibitor on Healthy Volunteers With Induced Hypotonic Hyponatremia - the DIVE Study
Empagliflozin (Jardiance)® is a sodium glucose co-transporter 2 (SGLT2)-Inhibitor, which is a new treatment option developed for patients with diabetes mellitus type 2.
- Trial name
- DIVE (NCT02729766)
- Testing
- Induced hypotonic hyponatremia - SIAD model, Empagliflozin 25mg Tbl
- Where
- Switzerland
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Type 2 Diabetes Mellitus
A Clinical Trial to Evaluate the Food Effect on Pharmacokinetic Profiles and Safety of CKD-379
This is a randomized, open-label, single dose, crossover, phase Ⅰ trial to evaluate the food effect on pharmacokinetic profiles and safety of CKD-379 in healthy volunteers
- Trial name
- NCT06204107
- Testing
- CKD-379(Empagliflozin+sitagliptin+metformin) Test drug, CKD-379(Empagliflozin+sitagliptin+metformin) Reference drug
- Where
- South Korea
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Type 1 Diabetes, Nephropathy, Diabetic
SGLT2 Adjunct in T1D
Effect of Sodium-Glucose Cotransporter (SGLT) 2 Inhibitors on Diabetic Nephropathy Progression in Adolescents with Type 1 Diabetes Mellitus
- Trial name
- NCT07591077
- Testing
- Empagliflozin (EMPA)
- Where
- Egypt
- Volunteers
- 86 people
- Sponsor
- Ain Shams University
Type 2 Diabetes
Comparison of Empaglifozin and Vildagliptin in Type 2 Diabetes Mellitus
The aim of this study is to perform a comparison of the efficacy and safety of empagliflozin and vildagliptin in patients with Type 2 Diabetes Mellitus open labelled, multi-centric, parallel, randomized control trial In Type 2…
- Trial name
- NCT05359432
- Testing
- Empagliflozin, Vildagliptin
- Where
- Pakistan
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Getz Pharma
Cystic Fibrosis-related Diabetes, Cystic Fibrosis
SGLT2 Inhibitor Therapy in Cystic Fibrosis-related Diabetes
This will be a placebo-controlled, randomized, double blind, crossover study with a 4 week wash out period. Collect pilot data on the safety, tolerability, and feasibility of empagliflozin therapy in overweight/obese patients…
- Trial name
- NCT06149793
- Testing
- Empagliflozin
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Minnesota